Emily M. Hinchcliff, MD, MPH, discusses the growing role of ADCs like mirvetuximab soravtansine for the treatment of patients with ovarian cancer.
Emily M. Hinchcliff, MD, MPH
Advertisement
Emily M. Hinchcliff, MD, MPH, is an assistant professor at Feinberg School of Medicine, Northwestern Medicine.
Articles by Emily M. Hinchcliff, MD, MPH
Emily M. Hinchcliff, MD, MPH, discusses how the addition of immunotherapy to chemotherapy has influenced the endometrial cancer treatment paradigm.
Emily Hinchcliff, MD, MPH, discusses the addition of dostarlimab to standard-of-care chemotherapy in patients with advanced/recurrent endometrial cancer.
Emily M. Hinchcliff, MD, MPH, discusses future research directions regarding the role of PARP inhibitors for the treatment of patients with ovarian cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5